ReviewFrontiers in nutrition2026
Bioavailability of dietary polyphenols and plant bioactives in functional foods: insights and limitations from
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review provides a comprehensive evaluation of how bioactive compounds within plant- and animal-derived food matrices interact with human physiology and metabolic pathways, with a particular focus on secondary metabolites synthesized or transformed via microbial pathways. The manuscript covers a diverse range of lipophilic and hydrophilic bioactive molecules, critically analysing these components from biological and technological perspectives. From a processing perspective, the mechanisms by which fermentation enhances antioxidant capacity by converting complex molecular structures into highly active aglycone forms are detailed. Concurrently, from an engineering perspective, the efficiency of nanoliposomes, solid lipid nanoparticles (SLNP), and biopolymeric carrier systems is assessed. Rather than claiming that encapsulation technologies can entirely overcome bioavailability limitations, this review critically assesses their potential to improve the stability, bioaccessibility and targeted release of sensitive components during gastrointestinal transit. Ultimately, by bridging microbial biotransformation with advanced delivery systems, this study offers a unified framework for optimizing the bioaccessibility of complex dietary compounds under simulated gastrointestinal conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.